Home / Health / The best performing sector last year, could be the top bet for 2019

The best performing sector last year, could be the top bet for 2019


The party might not be over yet, the sector should continue to be a solid play for 2019, too, according to Craig Johnson, chief market technician at Piper Jaffray.

“I think you let the winners run,” Johnson said Monday on CNBC’s “Trading Nation.” “If you look at a chart of the XLV, you can see that we pulled right back to the support area on the February lows. We never broke it. Many other sectors and the market in its entirety broke below those February lows but right here we’re not seeing it.”

The health-care ETF bounced off support at around $80 earlier in December, but did not break below its February and April lows. It is still in a correction down about 11 percent from its 52-week high.

“Two stocks that have caught our attention inside the health-care sector would be Medtronic, pulling back to a big identifiable support, and also Tandem which is also a name that has pulled right back to the rising 200-day moving average,” Johnson said. “Those are names that we would be buying in here now and we’d stick with the health-care trade.”

Gina Sanchez, CEO of Chantico Global, is also bullish on the health-care sector in the new year.

“You want to get into defensive sectors for 2019 and health care definitely fits that bill,” Sanchez said Monday on “Trading Nation.” “There are segments of health care that are actually going to be growing next year, segments like biotech and, quite frankly, digital health care.”

Defensive plays, such as health care, are considered safer bets in a shrinking economic environment where demand for their goods and services are less affected. Health care, alongside other defensive sectors such as utilities and REITs, typically offer a dividend and consistent growth.

“We think you should stick with something like health care for 2019,” added Sanchez.

About admin

Check Also

Big pharma blockbuster obesity drug battle is headed for $100 billion

Ozempic drug to treat diabetes. Courtesy: Ozempic In their most recent earnings reports, Novo Nordisk …